MedTrace Logo

The Effect of Two Different Oral Care Solutions on Ventilator-Associated Pneumonia and Oral Health of Mechanically Ventilated Patients in the Intensive Care Unit

NCT06966817 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-12

No results posted yet for this study

Summary

The aim of this observational study is to evaluate the effects of two different oral care solutions on ventilator-associated pneumonia and oral health in mechanically ventilated participants in the intensive care unit.

Did oral health improve in participants who used cetylpyridinium chloride? Did pneumonia develop? Did oral health improve in participants who used chlorhexidine chloride? Did pneumonia develop? The results will be evaluated by giving oral care to the participants with these solutions for 5 days with the same protocol.

Conditions

  • Ventilator-associated Pneumonia and Oral Health

Interventions

DRUG

control group(chlorhexidine)

The sponge swab is dipped in 0.25% chlorhexidine solution and used once for each part of the mouth, 4 times a day to provide oral care.

DRUG

Experimental Group(cetylpyridinium chloride)

The mouth is cleaned by dipping a sponge swab into 0.05% cetylpyridinium chloride solution and using it once for each part of the mouth, 4 times a day.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • bediye öztaş · Saglik Bilimleri Universitesi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2025-06-15
Completion
2025-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06966817 on ClinicalTrials.gov